CapsoVision anticipates FDA clearance for AI Highlights by end of Q3 as it targets Q4 CapsoCam Colon submission (NASDAQ:CV)
· seekingalpha.com
CapsoVision (CV) Q2 2026 earnings call recap: revenue growth, AI Highlights launch, FDA timeline update, margin/tariff pressures, and outlook—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...